Compare Fulford India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SUN PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SUN PHARMA FULFORD INDIA/
SUN PHARMA
 
P/E (TTM) x 398.8 84.7 471.0% View Chart
P/BV x 6.2 3.6 172.1% View Chart
Dividend Yield % 0.1 0.6 14.4%  

Financials

 FULFORD INDIA   SUN PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SUN PHARMA
Mar-20
FULFORD INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs942484 194.6%   
Low Rs450315 142.8%   
Sales per share (Unadj.) Rs691.4136.9 505.2%  
Earnings per share (Unadj.) Rs11.517.5 65.7%  
Cash flow per share (Unadj.) Rs15.426.0 59.1%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.31.0 28.7%  
Book value per share (Unadj.) Rs380.0188.7 201.4%  
Shares outstanding (eoy) m3.902,399.26 0.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.9 34.5%   
Avg P/E ratio x60.722.9 265.1%  
P/CF ratio (eoy) x45.315.4 294.9%  
Price / Book Value ratio x1.82.1 86.5%  
Dividend payout %17.422.9 76.1%   
Avg Mkt Cap Rs m2,714958,864 0.3%   
No. of employees `0000.417.8 2.5%   
Total wages/salary Rs m50563,624 0.8%   
Avg. sales/employee Rs Th6,073.018,490.6 32.8%   
Avg. wages/employee Rs Th1,137.43,582.6 31.7%   
Avg. net profit/employee Rs Th100.72,357.6 4.3%   
INCOME DATA
Net Sales Rs m2,696328,375 0.8%  
Other income Rs m1256,360 2.0%   
Total revenues Rs m2,822334,735 0.8%   
Gross profit Rs m-4669,898 -0.1%  
Depreciation Rs m1520,528 0.1%   
Interest Rs m103,027 0.3%   
Profit before tax Rs m5452,702 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m108,228 0.1%   
Profit after tax Rs m4541,868 0.1%  
Gross profit margin %-1.721.3 -8.1%  
Effective tax rate %17.715.6 113.2%   
Net profit margin %1.712.8 13.0%  
BALANCE SHEET DATA
Current assets Rs m1,738316,542 0.5%   
Current liabilities Rs m545157,064 0.3%   
Net working cap to sales %44.348.6 91.1%  
Current ratio x3.22.0 158.3%  
Inventory Days Days4888 55.4%  
Debtors Days Days4105 4.1%  
Net fixed assets Rs m12243,102 0.0%   
Share capital Rs m392,399 1.6%   
"Free" reserves Rs m1,443450,245 0.3%   
Net worth Rs m1,482452,645 0.3%   
Long term debt Rs m020,289 0.0%   
Total assets Rs m2,077682,525 0.3%  
Interest coverage x6.718.4 36.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.5 269.9%   
Return on assets %2.66.6 39.7%  
Return on equity %3.09.2 32.6%  
Return on capital %4.311.2 38.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1774,219 0.0%   
Fx outflow Rs m67327,964 2.4%   
Net fx Rs m-65646,255 -1.4%   
CASH FLOW
From Operations Rs m9065,548 0.1%  
From Investments Rs m105-25,888 -0.4%  
From Financial Activity Rs m-14-57,151 0.0%  
Net Cashflow Rs m181-13,857 -1.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 5.1 74.1%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 8.3 255.4%  
Shareholders   4,783 133,026 3.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS